TriSalus to raise $40M from stock sale

WESTMINSTER — TriSalus Life Sciences Inc. (Nasdaq: TLSI), a Westminster-based oncology company, plans to raise about $40 million through a stock sale. 

The company, which has developed a technology platform to treat hard-to-reach liver and pancreatic tumors, will sell more than 9.75 million shares of common stock at $4.10 per share. Lake Street Capital Markets will serve as the book-runner for the stock sale. 

Just before 9:50 a.m. Friday, Trisalus’s stock price was soaring. At $5.23 per share, the stock was up 13.45% in early trading.

Share on Facebook on LinkedIn